By now, almost everyone has heard about the meteoric rise of GLP-1 drugs, like Wegovy and Mounjaro. But a perhaps under-appreciated reality is that the GLP-1 obesity drugs are poised to drive record overall prescription drug sales growth and catapult Novo Nordisk and Eli Lilly into the upper echelon of Big Pharma companies by the…
Will GLP-1 drugs transition from obesity and diabetes to diverse clinical indications?
The explosive sales growth of GLP-1 drugs has analysts projecting that the antiobesity drugs could be a $44 billion market by 2030. Some observers are more upbeat, projecting that the sector could be worth more than $100 billion in the coming years. Pfizer CEO Albert Bourla projects that the market will reach $90 billion by…